Medication info

Foglime Met Sustained Release Tablet 10/500 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Korea Prime Pharma Co., Ltd.
Appearance
Pink, oval, film-coated tablets with a biconvex shape on both sides
Packaging
30 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 202204060 · Approved 2022.11.10

This product's status changed to Approval withdrawn on 2023.10.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetes drug treatment for whom adequate glycemic control cannot be achieved with monotherapy alone: When used as initial therapy in patients with no prior history of antidiabetes drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions to metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously taken. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medicine may be excreted in the stool as a soft hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2. In patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher but below 60 mL/min/1.73m2, and who have no other conditions that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum of 1000 mg daily. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, treatment with this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases. The risk of volume depletion with dapagliflozin should be considered.

Ingredients

Manufacturer
Korea Prime Pharma Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used to improve blood sugar control in adult patients with type 2 diabetes by combining dapagliflozin and metformin. It is particularly used as an adjunct to insulin and exercise therapy in patients who cannot achieve adequate blood sugar control alone. Additionally, for patients with type 2 diabetes whose blood sugar is not adequately controlled and have cardiovascular disease or risk factors, the effects of this medication on cardiovascular events should refer to healthcare professionals. This medication effectively assists in the treatment of type 2 diabetes and improves blood sugar management.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetes drug treatment for whom adequate glycemic control cannot be achieved with monotherapy alone: When used as initial therapy in patients with no prior history of antidiabetes drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions to metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously taken. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medicine may be excreted in the stool as a soft hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2. In patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher but below 60 mL/min/1.73m2, and who have no other conditions that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum of 1000 mg daily. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, treatment with this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases. The risk of volume depletion with dapagliflozin should be considered.

Precautions

This medication is used for the treatment of diabetes and helps to control blood sugar levels. Rarely, during the use of this medication, a serious condition called lactic acidosis may occur. If symptoms such as difficulty breathing, muscle pain, or fatigue appear, consult a doctor immediately. When taking other diabetes medications, hypoglycemic symptoms may occur, so blood sugar levels should be monitored closely. Patients with impaired kidney function, dehydration, severe infections, or heart-related problems should not take this medication, and the drug should be discontinued around the time of surgery or radiological examinations. Women who are pregnant or breastfeeding should not take this medication for safety. Elderly individuals or those with decreased kidney function should consult a doctor before taking this medication, and kidney function should be regularly monitored during treatment. This medication can cause genital infections or urinary tract infections in some patients, so treatment should be sought immediately if infection symptoms arise. Patients with reduced fluid volume or risk of low blood pressure should take caution while using this medication, and may temporarily stop it if necessary. During treatment, watch for signs of hypoglycemia, and dose adjustments may be required when used with insulin or other hypoglycemic agents. Patients with underlying conditions such as liver or kidney disease, or heart failure should use this medication only under medical supervision. In cases of overdose, seek immediate medical attention for appropriate treatment; the safety of this medication in children has not been established. This medication does not significantly affect driving or machine operation, but caution is needed as symptoms like dizziness may occur. Store this medication out of reach of children, and keep it in the original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 81 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • kidney dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • peptic ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbances
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • elevated blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarthritis
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • benign prostatic hyperplasia
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent air or moisture from entering. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius. This way, the effectiveness of the medication is maintained and degradation can be avoided.

Appearance and packaging

Appearance

Pink, oval, film-coated tablets with a biconvex shape on both sides

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.